Lacroix A, Feelders RA, Stratakis CA, Nieman LK: Cushing's syndrome. Lancet 2015, 386(9996):913-927.
Tritos NA, Biller BM: Cushing's disease. Handb Clin Neurol 2014,
124:221-234.
Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A: Complications
of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol 2016,
4(7):611-629.
Pivonello R, De Martino MC, De Leo M, Simeoli C, Colao A: Cushing's disease: the burden
of illness. Endocrine 2017,
56(1):10-18.
Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G: High cardiovascular risk in patients
with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004,
61(6):768-777.
Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke
JP, Pereira AM, Sorensen HT: Multisystem morbidity and mortality in Cushing's syndrome:
a cohort study. J Clin Endocrinol Metab 2013,
98(6):2277-2284.
Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B: Long-term remission rates
after pituitary surgery for Cushing's disease: the need for long-term surveillance.
Clin Endocrinol (Oxf) 2005,
63(5):549-559.
Fleseriu M, Loriaux DL, Ludlam WH: Second-line treatment for Cushing's disease when
initial pituitary surgery is unsuccessful. Curr Opin Endocrinol Diabetes Obes 2007, 14(4):323-328.
Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER, Jr.:
Late recurrences of Cushing's disease after initial successful transsphenoidal surgery.
J Clin Endocrinol Metab 2008,
93(2):358-362.
Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, Akker SA, Chew
SL, Drake WM, Monson JP et al: Long-term remission and recurrence rates in Cushing's disease: predictive factors
in a single-centre study. Eur J Endocrinol 2013, 168(4):639-648.
Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J, Reincke M, Stalla
GK: Long-term remission and recurrence rates after first and second transsphenoidal
surgery for Cushing's disease: care reality in the Munich Metropolitan Region. Eur J Endocrinol 2014,
170(2):283-292.
Pivonello R, De Leo M, Cozzolino A, Colao A: The Treatment of Cushing's
Disease.
Endocr Rev 2015, 36(4):385-486.
Cuevas-Ramos D, Fleseriu M: Treatment of Cushing's disease: a mechanistic
update.
J Endocrinol 2014, 223(2):R19-39.
Fleseriu M, Castinetti F: Updates on the role of adrenal steroidogenesis inhibitors
in Cushing's syndrome: a focus on novel therapies. Pituitary 2016,
19(6):643-653.
Daniel E, Newell-Price JD: Therapy of endocrine disease: steroidogenesis enzyme inhibitors
in Cushing's syndrome. Eur J Endocrinol 2015,
172(6):R263-280.
Stormann S, Schopohl J: New and emerging drug therapies for Cushing's
disease.
Expert Opin Pharmacother 2018, 19(11):1187-1200.
Forman SA: Clinical and molecular pharmacology of etomidate. Anesthesiology 2011, 114(3):695-707.
Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B: Infusion of low dose etomidate:
correction of hypercortisolemia in patients with Cushing's syndrome
and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990, 70(5):1426-1430.
Greening JE, Brain CE, Perry LA, Mushtaq I, Sales Marques J, Grossman AB, Savage MO:
Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe
paediatric Cushing's disease. Horm Res 2005,
64(3):140-143.
Preda VA, Sen J, Karavitaki N, Grossman AB: Etomidate in the management of hypercortisolaemia
in Cushing's syndrome: a review. Eur J Endocrinol 2012, 167(2):137-143.
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A,
Endocrine S: Treatment of Cushing's Syndrome: An Endocrine Society Clinical
Practice Guideline. J Clin Endocrinol Metab 2015,
100(8):2807-2831.
Tritos NA, Biller BM: Medical management of Cushing's disease. J Neurooncol 2014, 117(3):407-414.
McGrath M, Ma C, Raines DE: Dimethoxy-etomidate: A Nonhypnotic Etomidate Analog that
Potently Inhibits Steroidogenesis. J Pharmacol Exp Ther 2018,
364(2):229-237.
McGrath M, Yu Z, Jayakar SS, Ma C, Tolia M, Zhou X, Miller KW, Cohen JB, Raines DE:
Etomidate and Etomidate Analog Binding and Positive Modulation of gamma- Aminobutyric
Acid Type A Receptors: Evidence for a State-dependent Cutoff Effect. Anesthesiology 2018,
129(5):959-969.
Pejo E, Santer P, Jeffrey S, Gallin H, Husain SS, Raines DE: Analogues of etomidate:
modifications around etomidate's chiral carbon and the impact on in vitro and in vivo
pharmacology. Anesthesiology 2014,
121(2):290-301.
Frijlink HW, Eissens AC, Hefting NR, Poelstra K, Lerk CF, Meijer DK: The effect of
parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm
Res 1991,
8(1):9-16.
Shu HJ, Zeng CM, Wang C, Covey DF, Zorumski CF, Mennerick S: Cyclodextrins sequester
neuroactive steroids and differentiate mechanisms that rate limit steroid actions.
Br J Pharmacol 2007,
150(2):164-175.
McGrath M, Raines DE: Anesthetic Drug Discovery and Development: A Case Study of Novel
Etomidate Analogs. Methods Enzymol 2018,
603:153-169.
Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, Raines DE: Methoxycarbonyl-etomidate:
a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not
produce prolonged adrenocortical suppression. Anesthesiology 2009,
111(2):240-249.
Ge R, Pejo E, Cotten JF, Raines DE: Adrenocortical suppression and recovery after
continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl- methoxycarbonyl
metomidate. Crit Care 2013,
17(1):R20.
Roumen L, Sanders MP, Pieterse K, Hilbers PA, Plate R, Custers E, de Gooyer M, Smits
JF, Beugels I, Emmen J et al: Construction of 3D models of the CYP11B family as a tool to predict ligand binding
characteristics. Journal of computer-aided molecular design 2007,
21(8):455-471.
McCance DR, Hadden DR, Kennedy L, Sheridan B, Atkinson AB: Clinical experience with
ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1987,
27(5):593-599.
Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D: Ketoconazole treatment in
Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991, 35(4):347- 352.
Feelders RA, Hofland LJ, de Herder WW: Medical treatment of Cushing's syndrome: adrenal-blocking
drugs and ketaconazole. Neuroendocrinology 2010, 92 Suppl
1:111- 115.
Nieman LK: Medical therapy of Cushing's disease. Pituitary 2002,
5(2):77-82.
Tritos NA, Biller BM, Swearingen B: Management of Cushing disease. Nat Rev Endocrinol 2011,
7(5):279-289.
Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser
GM: Short and long-term responses to metyrapone in the medical management of 91 patients
with Cushing's syndrome. Clin Endocrinol (Oxf) 1991,
35(2):169-178.
Pejo E, Santer P, Wang L, Dershwitz P, Husain SS, Raines DE: gamma-Aminobutyric Acid
Type A Receptor Modulation by Etomidate Analogs. Anesthesiology
2015.
Jurd R, Arras M, Lambert S, Drexler B, Siegwart R, Crestani F, Zaugg M, Vogt KE, Ledermann
B, Antkowiak B et al: General anesthetic actions in vivo strongly attenuated by a point mutation in the
GABA(A) receptor beta3 subunit. Faseb J 2003, 17(2):250- 252.
Cotten JF, Forman SA, Laha JK, Cuny GD, Husain SS, Miller KW, Nguyen HH, Kelly EW,
Stewart D, Liu A et al: Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical
function. Anesthesiology 2010,
112(3):637-644.
Shanmugasundararaj S, Zhou X, Neunzig J, Bernhardt R, Cotten JF, Ge R, Miller KW,
Raines DE: Carboetomidate: an analog of etomidate that interacts weakly with
11beta- hydroxylase. Anesth Analg 2013,
116(6):1249-1256.